Treatment of Frey's Syndrome With "Ready to Use Liquid" Relabotulinumtoxin A (Relfydess).

Authors

Loris Zoller, Philipp Reddiess, Justus Müller-Goebel, Tobias Kleinjung, Daniel Runggaldier

Published in

Laryngoscope investigative otolaryngology. Volume 11. Issue 5. Pages e70618. Epub Oct 20, 2026.

Abstract

To describe the off-label intradermal use of ready-to-use liquid relabotulinumtoxinA (Relfydess) for symptomatic Frey's syndrome after parotidectomy.
A 72-year-old man with gustatory sweating and flushing after total parotidectomy and adjuvant radiotherapy, who had previously responded to conventional botulinum toxin A, underwent gustatory provocation, clinical mapping, and intradermal relabotulinumtoxinA injections using a 1-cm² grid. Clinical response and treatment-related adverse events were assessed at 6 weeks and 3 months.
At 6 weeks and 3 months, the patient reported symptom reduction comparable to his previous treatment with conventional botulinum toxin A. At 3 months, repeat gustatory stimulation elicited no visible sweating. No treatment-related adverse events were observed.
In this patient, ready-to-use liquid relabotulinumtoxinA provided sustained symptom control for 3 months without observed adverse events. This formulation may offer a practical off-label option for previously responsive patients, while product-specific potency units should not be considered interchangeable.
5.

PMID:
42908782
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.